Replies to post #3573 on Biotech Values

[DewDiligence]

Re: VEGF for heart disease:

>> The bigger problem in this approach is that the VEGF has to bind to its receptors on the cell surface. So the VEGF produced inside the cell with this approach has to properly cycle to the exterior of the cell, and then find its receptor. I think this raises the bar a bit on trying to demonstrate efficacy.<<

Thanks for the explanation. If I sounded unduly skeptical about this treatment, it’s because: 1) I had never heard of Corautus Genetics until now; and 2) St. Elizabeth’s Hospital in Boston (where the trial is taking place) has been known to try some weird therapies for heart disease. The late Dr Isner, who is lauded in the Corautus PR, was actually disciplined for ethical violations and nearly lost his license to practice medicine.